


## Hexanoylglycine-d<sub>11</sub>

<b>Cat. No.:</b>	HY-113150S		
<b>Molecular Formula:</b>	C <sub>8</sub> H <sub>4</sub> D <sub>11</sub> NO <sub>3</sub>		
<b>Molecular Weight:</b>	184.28		
<b>Target:</b>	Isotope-Labeled Compounds		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (542.65 mM; Need ultrasonic and warming)

Concentration	Solvent	1 mg	5 mg	10 mg
	Mass			
Preparing Stock Solutions	1 mM	5.4265 mL	27.1326 mL	54.2653 mL
	5 mM	1.0853 mL	5.4265 mL	10.8530 mL
	10 mM	0.5427 mL	2.7133 mL	5.4265 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Hexanoylglycine-d<sub>11</sub> is the deuterium labeled Hexanoylglycine[1].

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA